Tech Company Financing Transactions

Beacon Therapeutics Funding Round

On 7/3/2024, Beacon Therapeutics received $170 million in Series B financing from Forbion Capital Partners, Advent Life Sciences and Oxford Science Enterprises.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

14193 NW 119th Terrace, Suite #10
Alachua, FL 32615
USA

Phone

(386) 462-2204

Website

www.beacontx.com

Email Address

Undisclosed

Overview

Beacon Therapeutics is an ophthalmic gene therapy company founded to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. Our established scientific foundation combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two innovative and differentiated preclinical programs for prevalent and rare blinding diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

David Fellows

        

Chief Medical Officer

Nadia Waheed

        

Chief Scientific Officer

Abraham Scaria

        

Vice President

Eduardo Jacobo

        

Browse more venture capital transactions:

Prev: 7/3/2024: Tree.ly venture capital transaction
Next: 7/3/2024: Gendo venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to document funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary